David H Slepyan, MD | |
107 S Main St Ste D101, Coupeville, WA 98239-3547 | |
(360) 678-2128 | |
(360) 678-1878 |
Full Name | David H Slepyan |
---|---|
Gender | Male |
Speciality | Plastic Surgery - Surgery Of The Hand |
Location | 107 S Main St Ste D101, Coupeville, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629009857 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2082S0105X | Plastic Surgery - Surgery Of The Hand | MD00011222 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
David H Slepyan, MD 107 S Main St Ste D101, Coupeville, WA 98239-3547 Ph: (360) 678-2128 | David H Slepyan, MD 107 S Main St Ste D101, Coupeville, WA 98239-3547 Ph: (360) 678-2128 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Birth weight makes a difference to a child's future academic performance, according to new Northwestern University research that found heavier newborns do better in elementary and middle school than infants with lower birth weights.
Maricich Healthcare Communications has teamed with the American Medical Group Association (AMGA), the Council of Accountable Physician Practices (CAPP) and the Society for Healthcare Strategy & Market Development (SHSMD) to conduct the first healthcare executive survey to study change management communications for accountable healthcare.
India's Patent Office in New Delhi earlier this month rejected German drug maker Boehringer Ingelheim's application for a pediatric version of the antiretroviral drug nevirapine, consequently allowing local generic pharmaceutical companies such as Aurobindo and Cipla to continue marketing low-cost versions of the medicine in the domestic market, the Business Standard reports.
› Verified 7 days ago